rac-dimethyl 2-benzamidosuccinate | 86555-45-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: rac-dimethyl 2-benzamidosuccinate
• 英文别名: N-benzoyl-aspartic acid dimethyl ester；N-Benzoyl-asparaginsaeure-dimethylester；2-benzoylamino-succinic acid dimethyl ester；Dimethyl 2-benzamidosuccinate；dimethyl 2-benzamidobutanedioate
• CAS: 86555-45-5
• 化学式: C₁₃H₁₅NO₅
• 分子量: 265.266
• InChiKey: JAGPKJXEMSRCQL-UHFFFAOYSA-N

物化性质

• 熔点：
  92-95 °C(Solv: water (7732-18-5))
• 沸点：
  454.5±35.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  rac-dimethyl 2-benzamidosuccinate 在 phosphorus pentoxide 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 以59%的产率得到2-(5-methoxy-2-phenyl-oxazol-4-yl)-acetic acid methyl ester
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR
  [FR] COMPOSES HETEROCYCLIQUES UTILISES COMME MODULATEURS DES RECEPTEURS ACTIVES PROLIFERATEURS DU PEROXYSOME (PPAR), UTILES DANS LE TRAITEMENT ET/OU LA PREVENTION DE TROUBLES MODULES PAR UN PPAR

  摘要：

  本发明涉及一种式(I)的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。

  公开号：

  WO2005051945A1
• 作为产物：
  描述：

  Methyl Nα,Nε-dibenzoyl-2-vinyllysinate 在 臭氧 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 rac-dimethyl 2-benzamidosuccinate
  参考文献：
  名称：

  Synthesis of Quaternary Amino Acids Bearing a (2‘Z)-Fluorovinyl α-Branch:  Potential PLP Enzyme Inactivators

  摘要：

  Protected alpha-formyl amino acids, themselves available from the corresponding a-vinyl amino acids, are stereoselectively transformed into the (Z)-configured alpha-(2'-fluoro)vinyl amino acids via a three-step sequence. The route employs McCarthy's reagent, diethyl alpha-fluoro-alpha-(phenylsulfonyl)methyl phosphonate, and proceeds via the intermediate (E)-alpha-fluorovinyl sulfones and (E)-alpha-fluorovinyistannanes. The latter may either be exploited as novel cross-coupling partners for fluorovinyl branch extension or be globally deprotected, to provide the title compounds.

  DOI：

  10.1021/ol049422u

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• Microwave-Assisted Ruthenium-Catalysed <i>ortho</i> -C−H Functionalization of <i>N</i> -Benzoyl <i>α</i> -Amino Ester Derivatives
  作者：Nandini Sharma、Vijay Bahadur、Upendra K. Sharma、Debasmita Saha、Zhenghua Li、Yogesh Kumar、Jona Colaers、Brajendra K Singh、Erik V. Van der Eycken

  DOI：10.1002/adsc.201800458

  日期：2018.8.17

  A microwave‐assisted highly efficient intermolecular C−H functionalization sequence has been developed to access substituted isoquinolones using α‐amino acid esters as a directing group. This methodology enables a wide range of N‐benzoyl α‐amino ester derivatives to react via a Ru‐catalysed C−H bond activation sequence, to form isoquinolones with moderate to excellent yields. As an additional advantage

  微波辅助高效分子间C-H官能化序列已经发展到使用访问取代的异喹诺酮化合物α -氨基乙酸酯定向基团。这种方法可以使大量的N-苯甲酰基α-氨基酯衍生物通过Ru催化的CH键激活序列反应，以中等到极好的收率形成异喹诺酮类化合物。作为一个额外的优势，我们的策略被证明具有广泛的适用性，并且还使烯烃的反应能够提供链烯基化的苯甲酰胺的途径。该方法还扩展到异喹啉生物碱衍生物的合成，即。氧鸟嘌呤和二肽。所开发的方案既简单又便宜，避免了繁琐的后处理程序，并在MW辐射下有效地工作。
• Stereo-Controlled Asymmetric Bioreduction of α,β-Dehydroamino Acid Derivatives
  作者：Clemens Stueckler、Christoph K. Winkler、Mélanie Hall、Bernhard Hauer、Melanie Bonnekessel、Klaus Zangger、Kurt Faber

  DOI：10.1002/adsc.201100042

  日期：2011.5.9

  α,β‐Dehydroamino acid derivatives proved to be a novel substrate class for ene‐reductases from the ‘old yellow enzyme’ (OYE) family. Whereas N‐acylamino substituents were tolerated in the α‐position, β‐analogues were generally unreactive. For aspartic acid derivatives, the stereochemical outcome of the bioreduction using OYE3 could be controlled by variation of the N‐acyl protective group to furnish

  事实证明，α，β-脱氢氨基酸衍生物是“老黄酶”（OYE）家族中烯类还原酶的新型底物类别。而N-酰氨基取代基是在α位的耐受性，β-类似物普遍不反应。对于天冬氨酸衍生物，使用OYE3进行生物还原的立体化学结果可通过改变N-酰基保护基来提供相应的（S）-或（R）-氨基酸衍生物来控制。立体偏爱的这种转变是通过交换活化酯基团来改变底物结合力来解释的，这已通过2 H标记实验得到了证明。
• Modulators of peroxisome proliferator activated receptors (ppar)
  申请人：Gossett Stacy Lynn

  公开号：US20050075378A1

  公开（公告）日：2005-04-07

  The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

  本发明涉及一种I式化合物，以及其药学上可接受的盐、溶剂、水合物或立体异构体，该化合物在治疗X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及与X综合征相关的其他疾病以及心血管疾病方面有用。
• Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
  申请人：Henry James Robert

  公开号：US20080207685A1

  公开（公告）日：2008-08-28

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式为(I)的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物用于治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及其他与X综合征和心血管疾病相关的疾病。